{"id":"kaletra-current-dual-nrti-backbone","safety":{"commonSideEffects":[{"rate":"15-25","effect":"Diarrhea"},{"rate":"10-20","effect":"Nausea"},{"rate":"5-15","effect":"Abdominal pain"},{"rate":"5-10","effect":"Headache"},{"rate":"20-40","effect":"Lipid elevation (hypertriglyceridemia, hypercholesterolemia)"},{"rate":"2-5","effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL5984914","moleculeType":null,"molecularWeight":"296.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Kaletra contains lopinavir and ritonavir; lopinavir inhibits HIV protease, preventing the cleavage of viral polyproteins necessary for infectious particle maturation, while ritonavir acts as a pharmacokinetic booster by inhibiting cytochrome P450 metabolism. When combined with a dual NRTI backbone (typically two nucleoside reverse transcriptase inhibitors), this creates a potent three-drug antiretroviral therapy regimen that targets multiple steps of the HIV replication cycle.","oneSentence":"Kaletra is a protease inhibitor combination that blocks HIV protease to prevent viral replication, used as part of a three-drug antiretroviral regimen with two nucleoside reverse transcriptase inhibitors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:50:47.942Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced patients (as part of combination antiretroviral therapy)"}]},"trialDetails":[{"nctId":"NCT00145795","phase":"PHASE4","title":"A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2004-04","conditions":"HIV Infections","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lopinavir/ritonavir (LPV/r) + Current Dual NRTI Backbone"],"phase":"marketed","status":"active","brandName":"Kaletra + Current Dual NRTI Backbone","genericName":"Kaletra + Current Dual NRTI Backbone","companyName":"University of Chicago","companyId":"university-of-chicago","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Kaletra is used in combination with a current dual nucleoside reverse transcriptase inhibitor (NRTI) backbone as part of a treatment regimen for HIV infections. This combination is being studied in clinical trials, such as NCT00145795, to evaluate its effectiveness in improving the immune response to treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}